Compile Data Set for Download or QSAR
Report error Found 13 Enz. Inhib. hit(s) with all data for entry = 7976
TargetHistamine H1 receptor(Human)
Bridge Pharma

US Patent
LigandPNGBDBM94597((Z)-2-butenedioate;10-(1-methyl-4-piperidinylidene...)
Affinity DataIC50: 2.30E+3nMAssay Description:The specific binding of the radioactive ligand to the receptor was defined as the difference between total binding and nonspecific binding, determine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetHistamine H1 receptor(Human)
Bridge Pharma

US Patent
LigandPNGBDBM181150(US9333199, RS-NORKETOTIFEN (NORK) | US9138431, RS-...)
Affinity DataIC50: 1.10E+4nMAssay Description:The specific binding of the radioactive ligand to the receptor was defined as the difference between total binding and nonspecific binding, determine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetHistamine H1 receptor(Human)
Bridge Pharma

US Patent
LigandPNGBDBM50073179(CHEMBL1172 | Clarinex | Claritin-D | Claritin | SC...)
Affinity DataIC50: 1.60E+4nMAssay Description:The specific binding of the radioactive ligand to the receptor was defined as the difference between total binding and nonspecific binding, determine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetHistamine H1 receptor(Human)
Bridge Pharma

US Patent
LigandPNGBDBM227454(US9333199, R-NORKETOTIFEN (RNORK))
Affinity DataIC50: 1.70E+4nMAssay Description:The specific binding of the radioactive ligand to the receptor was defined as the difference between total binding and nonspecific binding, determine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetHistamine H1 receptor(Human)
Bridge Pharma

US Patent
LigandPNGBDBM227453(US9333199, S-NORKETOTIFEN (SNORK))
Affinity DataIC50: 2.30E+4nMAssay Description:The specific binding of the radioactive ligand to the receptor was defined as the difference between total binding and nonspecific binding, determine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetHistamine H1 receptor(Human)
Bridge Pharma

US Patent
LigandPNGBDBM50017674(Hydramine | Benylin | Silphen | (2-Benzhydryloxy-e...)
Affinity DataIC50: 8.40E+4nMAssay Description:The specific binding of the radioactive ligand to the receptor was defined as the difference between total binding and nonspecific binding, determine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetHistamine H1 receptor(Human)
Bridge Pharma

US Patent
LigandPNGBDBM22876(Sch 29851 | Claritin | CHEMBL998 | ethyl 4-{13-chl...)
Affinity DataIC50: 1.50E+6nMAssay Description:The specific binding of the radioactive ligand to the receptor was defined as the difference between total binding and nonspecific binding, determine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetHistamine H4 receptor(Human)
Bridge Pharma

US Patent
LigandPNGBDBM227453(US9333199, S-NORKETOTIFEN (SNORK))
Affinity DataKi:  1.10E+3nMAssay Description:The specific binding of the radioactive ligand to the receptor was defined as the difference between total binding and nonspecific binding, determine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetHistamine H4 receptor(Human)
Bridge Pharma

US Patent
LigandPNGBDBM181150(US9333199, RS-NORKETOTIFEN (NORK) | US9138431, RS-...)
Affinity DataKi:  2.00E+3nMAssay Description:The specific binding of the radioactive ligand to the receptor was defined as the difference between total binding and nonspecific binding, determine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetHistamine H4 receptor(Human)
Bridge Pharma

US Patent
LigandPNGBDBM227454(US9333199, R-NORKETOTIFEN (RNORK))
Affinity DataKi:  2.30E+3nMAssay Description:The specific binding of the radioactive ligand to the receptor was defined as the difference between total binding and nonspecific binding, determine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetHistamine H4 receptor(Human)
Bridge Pharma

US Patent
LigandPNGBDBM50017674(Hydramine | Benylin | Silphen | (2-Benzhydryloxy-e...)
Affinity DataKi:  1.10E+4nMAssay Description:The specific binding of the radioactive ligand to the receptor was defined as the difference between total binding and nonspecific binding, determine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetHistamine H4 receptor(Human)
Bridge Pharma

US Patent
LigandPNGBDBM50073179(CHEMBL1172 | Clarinex | Claritin-D | Claritin | SC...)
Affinity DataKi:  1.60E+4nMAssay Description:The specific binding of the radioactive ligand to the receptor was defined as the difference between total binding and nonspecific binding, determine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent

TargetHistamine H4 receptor(Human)
Bridge Pharma

US Patent
LigandPNGBDBM94597((Z)-2-butenedioate;10-(1-methyl-4-piperidinylidene...)
Affinity DataKi:  2.10E+4nMAssay Description:The specific binding of the radioactive ligand to the receptor was defined as the difference between total binding and nonspecific binding, determine...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/15/2017
Entry Details
Go to US Patent